Oxygen Biotherapeutics, Inc. Creates Web-based Shareholder Forum For Interactive Communications With Investors
COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company has established a web-based forum for shareholders to interact with management. The forum can be found in the Investor Relations section of the company website at www.oxybiomed.com.
"Earlier this year the SEC amended the proxy rules to encourage creation of internet-based electronic forums for shareholders and management to interact with each other. I think that establishing this shareholder forum will improve our communications with shareholders, help us to better understand what they're thinking, as well as help us to be better understood by the investment community," said company chairman and CEO Chris J. Stern, DBA. "We want this to be a credible and more accurate alternative to those third-party message boards. Shareholders will be able to post comments, discuss company-related matters, and pose their questions to management. Unlike third-party investment message boards, the management of our company will be reading everything that's posted on our shareholder forum. I'll have a blog there and other members of management will also be posting to it as appropriate. The forum is now available on our website and I encourage our shareholders to register and participate."
While anyone who visits the company website may read anything posted to the forum, only verified company shareholders will be allowed to post or submit questions on the forum.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring. The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product and an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs and medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. For further information, visit www.oxybiomed.com.